Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3862 - Tumor mutation burden and microsatellite instability in colorectal cancer


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Francesca Fenizia


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


F. Fenizia1, R. Esposito Abate1, R. Pasquale1, C. Roma1, M. Lambiase1, N. Chicchinelli1, P. Graziano2, G. Botti3, F. Tatangelo4, G. Scognamiglio4, F. Pietrantonio5, N. Normanno1

Author affiliations

  • 1 Translational Research, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Pathology, IRCCS " Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo/IT
  • 3 Scientific Direction, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 4 Pathology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 5 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3862


The role of tumour mutation burden (TMB) as predictive biomarker of response to immune checkpoint inhibitors (ICI) is being explored in colorectal cancer (CRC). Microsatellite instability status (MSI) is currently used to identify CRC patients who may benefit from ICI. However, TMB values vary significantly among MSI CRC. In addition, selected microsatellite stable (MSS) with high TMB might also benefit treatment with ICI.


TMB evaluation was performed with the Oncomine Tumor Mutation Load Assay (OTML, Thermofisher) on the Ion S5XL platform. Data analysis was carried out using Ion Reporter Software v5.10. TMB was calculated as the total number of non-synonymous somatic single nucleotide variants (SNVs) and indels divided by number of bases sequenced. MSI status was analysed by means of the Idylla MSI assay (Biocartis), which evaluates the presence of mutations in 7 novel MSI loci.


TMB analysis was performed on 106 formalin-fixed paraffin embedded CRC samples and the data were compared with the MSI results. The Idylla assay classified 68 samples as MSS and 38 samples as microsatellite instable (MSI-H). The TMB values ranged from zero to 21.22 (median: 5.005) in the MSS and from 13.42 to 204.8 in the MSI-H group (median: 25.66), with a significant difference in median values (P < 0.0001). A significant difference in TMB values was also observed when the number of mutated MSI-associated loci was ≥2 versus <2. We next correlated the presence of mutations in a group of driver genes with the TMB values. Significantly different median TMB values were registered when a BRAF (Mann Whitney p value: 0.0023) or PIK3CA mutation (p value: 0.0082) was present, but not when KRAS alterations were detected.


The TMB values assessed with the OTML assay strongly correlated with MSI status in CRC. However, significant heterogeneity in TMB levels were detected among both MSI and MSS tumors, suggesting that TMB testing might provide additional information on sensitivity to ICI in CRC. The correlations with driver gene alterations might help in selecting tumors to be tested for TMB.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.